Tagged with B

Portugal P-BIO, Portugal’s leading association for its biotech industry, is approaching a quarter century in existence. Its president, Simão Soares, tells PharmaBoardroom that there has been “substantial positive change” in the country’s biotech environment in these years, and – while the overall industry is still relatively modest in size compared to…

UAE Drawing on a quarter of a century of pharmaceutical industry experience, over 20 years of which has been spent in the UAE, Ayman Mokhtar today heads up Middle East, North Africa and Eurasia operations for Viatris. A global healthcare company with a broad range of products, Viatris is continually working…

China A roundup of some of the latest news from Chinese pharma including CanSino’s Gates Foundation grant for polio vaccine R&D; Merck’s deal with Jiangsu Hengrui; the license agreement between GSK and Hansoh Pharma, and the China-based starteup Biotheus’ oncology partnership with BioNTech.   Chinese and Foreign Pharmaceutical, Medical Device Firms…

Morocco Pierre Fabre has been present in the Moroccan market for nearly 40 years. Pierre Behnam, the company’s director for Africa, Middle-East and Türkiye discusses its strategy for bringing innovation and targeted therapies to patients in Morocco.   I am confident that over time, with joint work between innovators and health…

Morocco Dr Anthony Y. Lauw, GM & Head of Human Pharma Northwest Africa at Boehringer Ingelheim, explains the operations of a cluster that has typically worked with local partners, but that now has also opened a new scientific office in Casablanca with the idea of expanding the company’s on-ground operations in…

Spain A roundup of the latest news from Spanish pharma, including Almirall’s licensing deal with EpimAb Biotherapeutics; the opening of Insud Pharma’s oligonucleotides centre in India, and Esteve Química’s new FDA-cleared manufacturing site.   Almirall licenses bispecific platform in $210m EpimAb deal (BioProcess International) EpimAb Biotherapeutics has out-licensed the rights for…

Denmark LEO Pharma has been in the midst of a shakeup since the beginning of 2022. After naming a new CEO and announcing a major restructuring, the Danish dermatology pharma has let a considerable number of employees go, closed research centres and restructured its R&D team. While LEO’s financials look promising…

Global After positions at Novartis and Merck, Bettina Bauer, a trained scientist, joined Gilead in 2019 as VP and general manager of its German affiliate. Today, as the VP of the company’s global commercial strategy and operations for HIV, COVID-19, and emerging viruses, she discusses the company’s strides in HIV prevention…

Brazil Part of PharmaBoardroom’s new country-focused series on market access and health technology assessment (HTA), this piece is focused on HTA Dossiers and Data requirements in the Brazilian pharma market today. Buy The Pharma Legal Handbook: Market Access & HTA – Brazil here for £359.   HTA DOSSIERS Have local authorities published…

Switzerland As former parent company Novartis centres its efforts on its “pure-play” innovative medicines business, Sandoz is increasingly betting on biosimilars. Having already launched a version of AbbVie’s blockbuster arthritis treatment Humira, the newly spun-off company has been gearing up for its independence by preparing additional biosimilar launches, signing big partnership…

Hong Kong While much of PharmaBoardroom’s recent report on Hong Kong and the Greater Bay Area looks at how Hong Kong is attempting to position itself as a development and financing hub for health tech start-ups, just as important are the multinational pharma companies with commercial operations in the city, providing Hong…

China After four years away, Brendan Shaw recently returned to China to attend the ChinaBio Innovation and Investment Conference in Suzhou. Although geopolitical tensions, the fallout from COVID-19, and local market challenges have dampened stakeholder optimism around China somewhat in the last few years, Shaw feels that the country still has…